Got a Double Chin? Get rid of it with new FDA approved Kybella™!
Dr. Cobos is one of the first physicians in the US to use Kybella Treatments and the ONLY Board Certified Dermatologist in North Orange County trained in this procedure.
Call for your consultation today 714-870-7546.
We are excited to introduce Kybella™! Submental fullness, also known as “a double chin,” is a common yet often undertreated condition that can cause someone with a normal balanced look to appear older and heavier. Submental fullness can affect adults – both women and men – of all ages, weight and gender. Submental fullness is often influenced by multiple factors including aging and genetics, and can often be resistant to diet and exercise.
click image to enlarge
Kybella™ is the first and only FDA approved injectable drug that helps you reduce submental fat and get rid of that double chin. Kybella™ causes the destruction of fat cells, which are then naturally broken down and absorbed by your body. Multiple treatments are recommended to achieve your desired look.
Kybella Pre and Post treatment photos:
These are unretouched photos of clinical trial patient taken before and after treatment with KYBELLA™ (deoxycholic acid) injection. Individual results may vary.
All Photos are the property of Allergan, Inc.
KYBELLA™ (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Important Safety Information
- KYBELLA should only be administered by a trained healthcare professional.
- KYBELLA is contraindicated in the presence of infection at the injection sites.
- Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage.
- Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days).
- Difficulty swallowing (dysphagia) occurred in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA in these patients as current or prior history of dysphagia may exacerbate the condition.
- In clinical trials, 72% of subjects treated with KYBELLA experienced injection site hematoma/bruising. KYBELLA should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
- To avoid the potential of tissue damage, KYBELLA should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.